Better Outcomes for Patients will Provide Better Business Outcomes

It will not have escaped your attention that ‘patient centricity’ has become something of a catchphrase in the last couple of years: mission statements and company announcements are full of it. Cynics have yet to be convinced, but some believers in pharma are working to win them over. John McCarthy, VP Global Commercial Excellence at AstraZeneca, thinks he has the tools to make the idea something more concrete. The international team he leads has a daunting remit: to build and deliver capabilities to drive commercial success, transform the healthcare experience and improve the lives of millions of patients. Measuring the journey In short, he is leading the charge to make AstraZeneca a patient-centric organization. To know you are achieving this broad and ambitious set of aims requires a laser-like focus on outcomes, and McCarthy believes it is vital to build in measurement from the start. However, there may be a limit to the usefulness of traditional KPIs in this environment. “There are many ways to measure along this journey,” McCarthy says. “We’re probably not measuring patient centricity at a corporate level just yet, but if you’re doing journey mapping and understand the problems, that is probably a measure. KPIs too often bring you back to the business outcome only.” Instead, he suggests, you need to look for evidence that you are solving a problem for patients. The $64 million question which follows on from this – an...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Aeyung Kim, Jin Yeul Ma
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Background The relationship between admission left ventricular (LV) volumes, regional contractility and persistent ST elevation in first anterior ST elevation myocardial infarction (STEMI) with evolution of LV volumes at 12 months remains inconclusive. Thus possible differences among patients with reverse dilatation (RD), stationary dilatation (SD) or progressive dilatation (PD) at 12 months based on left ventricle end-systolic volume (LVESV) index changes were investigated. Patients and methods ECG and echocardiographic features of 394 1-year survivors of anterior STEMI were analyzed at admission, 6 and 12 months in ...
Source: Coronary Artery Disease - Category: Cardiology Tags: Myocardial Infarction Source Type: research
Background Elevated neutrophil-to-lymphocyte ratio (NLR) is an indirect marker of inflammation, and is associated with adverse clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to investigate the usefulness of NLR to predict procedural adverse events is patients who underwent primary percutaneous coronary intervention (PCI). Patients and methods Consecutive patients with STEMI who underwent primary PCI were divided into low and high NLR, whereas high was defined as an NLR value above 75° percentile (≥9.45). The occurrence of procedural complications...
Source: Coronary Artery Disease - Category: Cardiology Tags: Myocardial Infarction Source Type: research
Conclusion In patients with ACS, elevated admission lactate level is an independent predictor of 30-day and 180-day all-cause mortality.
Source: Coronary Artery Disease - Category: Cardiology Tags: Myocardial Infarction Source Type: research
Objectives Coronary bifurcations are common in daily practice of percutaneous coronary intervention and remain one of the most challenging lesions, but it is still unknown how characteristics, treatment strategy, and outcomes have changed over the last decade of drug-eluting stents (DES) era. We evaluated characteristics of treatment pattern and outcomes for patients with bifurcation disease over time in real-world clinical practice. Patients and methods A total of 7282 patients with coronary bifurcation lesions were pooled from the Interventional Cardiology Research Incorporation Society-Drug-Eluting Stents registry ...
Source: Coronary Artery Disease - Category: Cardiology Tags: Coronary Intervention Source Type: research
Conclusion Blood type A was found as a risk factor for MI. Higher arachidonic acid-induced aggregation in group O and higher PRI in group A against aspirin and P2Y12 inhibitor treatment, respectively, may suggest alternative antiplatelet therapies for PRs with these blood types.
Source: Coronary Artery Disease - Category: Cardiology Tags: Coronary Intervention Source Type: research
Conclusion For patients with very long native coronary artery disease, R-ZES and EES implantation showed comparable angiographic and clinical outcomes through 1 year of follow-up.
Source: Coronary Artery Disease - Category: Cardiology Tags: Coronary Intervention Source Type: research
In this study we demonstrate the use of clustered regularly interspaced short palindromic repeats (CRISPR)-based epigenome editing to alter cell response to inflammatory environments by repressing inflammatory cytokine cell receptors, specifically TNFR1 and IL1R1. This has applications for many inflammatory-driven diseases. It could be applied for arthritis or to therapeutic cells that are being delivered to inflammatory environments that need to be protected from inflammation." In chronic back pain, for example, slipped or herniated discs are a result of damaged tissue when inflammation causes cells to create ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Editor’s Note: This essay contains excerpts from Extreme Measures: Finding a Better Path to the End of Life, coming February 21st, 2017 from Penguin-Random House. A few years ago, while at a family get-together, I sat across from a retired hospice social worker named Terry. I am a physician whose practice alternates between attending on the wards of an inner-city intensive care unit and serving as a consultant on the hospital’s palliative care team. I didn’t set out to practice this uncommon combination of medical specialties. I started out totally dedicated to using the miraculous technologies in my crit...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: End of Life & Serious Illness Health Professionals Hospitals 30-day mortality statistic advance directive Palliative Care Source Type: blogs
I am in a perpetual abusive relationship with hypochondria; I desperately want to get away from it, but somehow it controls my brain. I've had hypochondriac tendencies (more officially known as "illness anxiety disorder") for as long as I can remember. I'm not sure who or what to blame and the source of the disorder is irrelevant; it's the cure I'm after. Hypothesis theories for my hypochondria: Throughout my childhood, my mother perpetually complained of a bad heart and threatened to faint, falling back on her stash of smelling salts in her purse. The best birthday present I ever got was the Merck Medical Ma...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
More News: AstraZeneca | Back Pain | Cancer | Cancer & Oncology | Cardiology | Education | Environmental Health | Health | Heart | Heart Attack | Heart Transplant | Hospitals | Learning | Lung Cancer | Lung Transplant | Medical Devices | Pain | Pharmaceuticals | Science | Transplant Surgery | Transplants | Universities & Medical Training